SCHEMBL13401495

SCHEMBL13401495

Cc1c(Br)cc(NCC(=O)/N=N/Cc2cc([N+](=O)[O-])ccc2O)cc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIG1 P18858 2/20 0.58
LIG3 P49916 1/20 0.58
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
NPC1 O15118 1/20 0.42
THRB P10828 1/20 0.42
ALB P02768 1/20 0.39
APP P05067 1/20 0.39
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PITRM1 Q5JRX3 1/20 0.37
LMNA P02545 3/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CTSB P07858 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
HTT P42858 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19298155 0.73 LIG1 (1.00) LIG1LIG3MAPTKDM4ETHRB
SCHEMBL13401789 0.73 LIG1 (1.00) LIG1LIG3MAPTKDM4ETHRB
SCHEMBL4231830 0.65 ALDH1A1 (0.58) MAPTTHRBAPPMEN1KMT2A
SCHEMBL22624691 0.65 APP (0.66) MAPTKDM4EALBAPPMEN1
SCHEMBL10417384 0.64 L3MBTL1 (0.55) MAPTKDM4ETHRBAPPMEN1
SCHEMBL13827067 0.64 GPR35 (0.56) THRBAPPMEN1KMT2AGAA
SCHEMBL131912 0.64 GPR35 (0.56) THRBAPPMEN1KMT2AGAA
SCHEMBL51277 0.64 GPR35 (0.60) MAPTTHRBAPPMEN1KMT2A
SCHEMBL18857325 0.63 GPR35 (0.51) THRBALBAPPMEN1KMT2A
SCHEMBL5170527 0.63 CTSB (0.54) THRBALBAPPMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445537-B2 Compounds that inhibit human DNA ligases and methods of treating cancer STC.UNM (US) 2013-05-21 US disclosed
US-8445537-B2 Compounds that inhibit human DNA ligases and methods of treating cancer STC.UNM (US) 2013-05-21 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 LIG1 1/4885LIG3 3/4885MAPT 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.